News
-

MK-677 Study: More Lean Mass, No Strength Gain
The 2008 older-adult trial raised hormone levels and fat-free mass. It didn't show stronger muscles or better everyday physical function.
-

Semaglutide Alcohol Use Disorder Trial: Results
A 48-person trial found less drinking on some measures and lower cravings. It did not establish lasting recovery or a treatment plan for alcohol use disorder.
-

GHK-Cu Wound Healing Study: A Mixed Record
A diabetic-ulcer gel trial reported greater wound shrinkage. Other wound trials complicate the answer, and the findings cannot establish injection benefits.
-

HOMA-IR Explained: What Your Score Means
HOMA-IR estimates insulin resistance from fasting blood sugar and insulin. The formula is simple; interpreting the result takes more than a cutoff.
-

NAD for Addiction: What the Evidence Shows
NAD+ hasn't been established as an addiction treatment. The human reports leave major questions about withdrawal, craving and lasting recovery.
-

PT-141 and Alcohol: What the Label Actually Says
Vyleesi's alcohol study was reassuring but small. Oral naltrexone, blood pressure, and the actual prescription still affect the review.
-

Does Semaglutide Cause Erectile Dysfunction?
Erection problems have been reported during semaglutide treatment, but a direct cause hasn't been established. Labels and studies tell different parts of the story.
-

Imcivree Prescribing Information, in Plain English
Imcivree’s label covers a few specific causes of obesity. Here are its age limits, dose decisions, skin changes, other warnings and storage rules in plain language.
-

10 Questions to Ask Before MOTS-c
Ten questions cover the evidence, medicines, medical history, sport rules and follow-up that a MOTS-c visit needs to address.
-

Who Discovered Growth Hormone? Evans, Li and Raben
Evans and Long found the growth signal in animals. Li helped isolate the human hormone, and Raben brought it into clinical care.
-

Ozempic Nails: What the 2026 GLP-1 Nail Study Found
A new October 2026 dermatology survey linked GLP-1 use to higher self-reported nail detachment. Here is what the study actually measured, why U.S. drug labels list no nail disorders, and when a lifted nail needs a doctor.
-

PT-141 Myths: 10 Claims Checked
Ten familiar PT-141 claims, checked against the Vyleesi label and human studies. What holds up, what stretches the findings, and what remains unknown.
-

Stomach Bug on Ozempic or Zepbound: What the Labels Say
Vomiting and diarrhea from a winter virus can drain fluids fast when you take a GLP-1 medication. Here is how the official labels handle dehydration warnings, missed doses, and calling your doctor.
-

When to Take NAD+: Morning, Night, or Around Workouts?
The October 17, 2026 research searches identified no human trial comparing morning with evening NAD+ injections. Your actual schedule comes from your prescribing clinician and the dispensing pharmacy's instructions.
-

Who Invented CJC-1295? ConjuChem's Albumin Idea
A Montreal team built CJC-1295 to make a short-lived hormone signal last longer. Its history explains the original molecule, the halted trial and today's naming confusion.
-

Daylight Saving Time Medication Schedule for Fall
The fall clock change raises different questions for bedtime prescriptions, weekly injections and insulin devices. The written schedule is the starting point.
-

PT-141 vs Addyi: As-Needed Shot vs Nightly Tablet
Branded Vyleesi (bremelanotide, or PT-141) is an as-needed injection for premenopausal women, while Addyi (flibanserin) is a nightly tablet for women under 65. Their schedules, side effects, and safety rules differ sharply.
-

Should I Take Thymosin Alpha 1? How Doctors Decide
A pattern of frequent infections on an immune-suppressing medicine raises specific questions before any peptide comes up. We walk through one fictional patient profile to show what a clinician checks first, what human studies tested, and where the evidence stops.
-

Tirzepatide Bloating: Trial Rates and Warning Signs
Tirzepatide can cause a full or swollen belly, though clinical trials recorded visible abdominal distension in 3% to 4% of weight-management patients. Here is what the brand labels report, why slowed digestion plays a role, and which symptoms need a doctor right away.
-

CJC-1295 Ipamorelin Myths: 10 Claims Checked
CJC-1295 and ipamorelin can prompt the pituitary gland to release growth hormone. Ten common claims about muscle, blood sugar, sports rules, and testing go further than the published studies support.
Page 3 of 27 · 528 articles